Roche, Lilly drugs chosen for Alzheimer's prevention trial
Oct 10 (Reuters) - Roche Holding AG's experimental drug gantenerumab and Eli Lilly & Co's solanezumab have been chosen to be tested in a high-profile global Alzheimer's disease prevention trial, and a second Lilly medicine is being considered for potential inclusion in the study, Washington University said on Wednesday.
The St. Louis-based University said the trial, expected to begin in early 2013, will enroll 160 patients with inherited gene mutations that typically lead to Alzheimer's disease at a young age.
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video